Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Recruiting 5Active not recruiting 5Completed 3Not yet recruiting 1

Sponsor Class

OTHER 4NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Other hematologic neoplasm 1

Conditions

Uterine Cervical Neoplasms 1NSCLC 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 382Carboplatin 279Specimen Handling 266Nivolumab 256Magnetic Resonance Spectroscopy 247Cyclophosphamide 242Cisplatin 217Paclitaxel 208Radiotherapy 196Biopsy 171Gemcitabine 158Dexamethasone 149durvalumab 148atezolizumab 128Rituximab 123Doxorubicin 117Bevacizumab 115Ipilimumab 114Lenalidomide 113Radiation 111Pemetrexed 104Docetaxel 104Etoposide 102venetoclax 98fludarabine 97Radiosurgery 94Capecitabine 94Fluorouracil 93Oxaliplatin 91Prednisone 90

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Tyrosine Kinase Inhibitors × 1 year × Clear all
NCT03817398 2026-05-20

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

Children's Oncology Group

Phase 2 Active not recruiting
110 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT03611738 2026-05-15

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Active not recruiting
21 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Sun Yat-sen University

Phase 2 Active not recruiting
30 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT05824481 2026-03-10

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

Sun Yat-sen University

Phase 2 Active not recruiting
32 enrolled
Gynecologic

Endometrial Neoplasms

NCT04318938 2026-03-02

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Active not recruiting
118 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡